Natera (NTRA) to Announce Quarterly Earnings on Thursday

Posted by Brenda Bartman on Jul 30th, 2026

Natera (NASDAQ:NTRA – Get Free Report) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.4939) per share and revenue of $661.2430 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Natera Stock Up 0.6%

Shares of NTRA opened at $253.82 on Thursday. The stock has a market cap of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. Natera has a 12-month low of $131.81 and a 12-month high of $288.04. The business has a 50-day simple moving average of $244.16 and a two-hundred day simple moving average of $221.65.

More Natera News

Here are the key news stories impacting Natera this week:

Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Barclays reduced their price target on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday, June 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. UBS Group set a $260.00 target price on shares of Natera in a report on Wednesday, June 24th. Finally, BTIG Research set a $275.00 price target on shares of Natera and gave the company a “buy” rating in a research report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $267.83.

View Our Latest Stock Report on NTRA

Insider Buying and Selling

In other news, insider John Fesko sold 931 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $236,539.17. Following the completion of the sale, the insider owned 184,069 shares of the company’s stock, valued at approximately $46,766,410.83. This represents a 0.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 1,863 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.38, for a total value of $464,594.94. Following the transaction, the chief financial officer owned 52,432 shares of the company’s stock, valued at $13,075,492.16. This trade represents a 3.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 178,862 shares of company stock worth $40,416,335. Corporate insiders own 5.05% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. State Street Corp increased its position in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after buying an additional 72,087 shares during the period. Coatue Management LLC increased its position in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares during the period. AQR Capital Management LLC raised its stake in Natera by 8.3% during the fourth quarter. AQR Capital Management LLC now owns 2,599,299 shares of the medical research company’s stock worth $595,473,000 after buying an additional 199,234 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Natera by 8.9% during the fourth quarter. Invesco Ltd. now owns 1,329,166 shares of the medical research company’s stock worth $304,499,000 after buying an additional 108,437 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.